

# Zoltan Mari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351514/publications.pdf>

Version: 2024-02-01

100  
papers

7,403  
citations

147801

31  
h-index

58581

82  
g-index

103  
all docs

103  
docs citations

103  
times ranked

9971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Application of Cerebellar Transcranial Direct Current Stimulation Does Not Improve Motor Learning in Parkinson's Disease. <i>Cerebellum</i> , 2022, 21, 333-349.	2.5	9
2	Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 38-42.	2.2	15
3	The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 810860.	3.4	17
4	Remote measurement and home monitoring of tremor. <i>Journal of the Neurological Sciences</i> , 2022, 435, 120201.	0.6	7
5	Dystonia and Tremor. <i>Neurology</i> , 2021, 96, e563-e574.	1.1	46
6	Suicide and Lewy body dementia: Report of a Lewy body dementia association working group. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 373-382.	2.7	9
7	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 958-968.	1.2	17
8	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	10.2	74
9	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 312.	9.0	83
10	Global Variability in Deep Brain Stimulation Practices for Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 667035.	2.0	9
11	Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation. <i>Brain</i> , 2021, 144, 2837-2851.	7.6	14
12	Dementia with Lewy bodies: emerging drug targets and therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 603-609.	4.1	6
13	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 97-100.	2.2	23
14	Hippocampal correlates of episodic memory in Parkinson's disease: A systematic review of magnetic resonance imaging studies. <i>Journal of Neuroscience Research</i> , 2021, 99, 2097-2116.	2.9	5
15	Critical Appraisal of Amyloid Lowering Agents in AD. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 39.	4.2	57
16	Anxiety in Parkinson's Disease: A Systematic Review of Neuroimaging Studies. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 280-294.	1.8	6
17	Telemedicine and Deep brain stimulation - Current practices and recommendations. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 199-205.	2.2	18
18	Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1563-1601.	2.6	8

#	ARTICLE	IF	CITATIONS
19	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	7.4	80
20	Videoconferencing Software Options for Telemedicine: A Review for Movement Disorder Neurologists. Frontiers in Neurology, 2021, 12, 745917.	2.4	9
21	North American survey on impact of the COVID-19 pandemic shutdown on DBS care. Parkinsonism and Related Disorders, 2021, 92, 41-45.	2.2	8
22	Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease. Parkinsonism and Related Disorders, 2021, 93, 97-102.	2.2	13
23	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
24	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology, 2020, 94, e774-e784.	1.1	24
25	An Acute Application of Cerebellar Transcranial Direct Current Stimulation Does Not Improve Motor Performance in Parkinson's Disease. Brain Sciences, 2020, 10, 735.	2.3	11
26	Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care. Parkinsonism and Related Disorders, 2020, 80, 35-40.	2.2	18
27	Timing of the Sense of Volition in Patients With Schizophrenia. Frontiers in Neuroscience, 2020, 14, 574472.	2.8	5
28	Neural Correlates of Freezing of Gait in Parkinson's Disease: An Electrophysiology Mini-Review. Frontiers in Neurology, 2020, 11, 571086.	2.4	26
29	Global Survey on Telemedicine Utilization for Movement Disorders During the COVID-19 Pandemic. Movement Disorders, 2020, 35, 1701-1711.	3.9	73
30	Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future. Journal of Parkinson's Disease, 2020, 10, 911-913.	2.8	35
31	Genetic Mutations and Deep Brain Stimulation. , 2020, , 59-64.		0
32	Resting state functional connectivity in levodopa non responsive Parkinson's disease patients with freezing of gait. Parkinsonism and Related Disorders, 2020, 79, e8.	2.2	0
33	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. Journal of the Neurological Sciences, 2019, 405, 116413.	0.6	14
34	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	2.2	12
35	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. American Journal of Geriatric Psychiatry, 2019, 27, 712-719.	1.2	13
36	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 30.	5.3	32

#	ARTICLE	IF	CITATIONS
37	Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality. American Journal of Geriatric Psychiatry, 2018, 26, 700-710.	1.2	5
38	Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome. JAMA Neurology, 2018, 75, 353.	9.0	186
39	Telemedicine Use for Movement Disorders: A Global Survey. Telemedicine Journal and E-Health, 2018, 24, 979-992.	2.8	22
40	Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, e131-e139.	2.7	9
41	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 47, 50-56.	2.2	14
42	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38.	1.5	9
43	Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
44	What predicts falls in Parkinson disease?. Neurology: Clinical Practice, 2018, 8, 214-222.	1.6	23
45	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 53, 108-109.	2.2	1
46	Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 8-14.	2.2	37
47	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature Medicine, 2018, 24, 931-938.	30.7	712
48	Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. Journal of Alzheimer's Disease, 2018, 64, 597-606.	2.6	69
49	Personality and reported quality of life in Parkinson's disease. International Journal of Geriatric Psychiatry, 2017, 32, 324-330.	2.7	19
50	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. Journal of the Neurological Sciences, 2017, 377, 137-143.	0.6	27
51	S94 Update on technological advancements in invasive neurophysiological activity monitoring and deep-brain stimulation. Clinical Neurophysiology, 2017, 128, e209.	1.5	0
52	Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images. NeuroImage: Clinical, 2017, 16, 539-544.	2.7	76
53	National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 2017, 89, 1152-1161.	1.1	169
54	Changes in Verbal Fluency in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 84-89.	1.5	13

#	ARTICLE	IF	CITATIONS
55	The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?. <i>Frontiers in Neuroscience</i> , 2016, 10, 170.	2.8	55
56	Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the cd probe study. <i>Toxicon</i> , 2016, 123, S20.	1.6	0
57	Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. <i>NeuroImage: Clinical</i> , 2016, 12, e1-e9.	2.7	59
58	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 107-114.	2.2	21
59	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 102-106.	2.2	8
60	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 109-115.	1.5	21
61	Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1171-1180.	1.2	28
62	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. <i>Movement Disorders</i> , 2016, 31, 1874-1882.	3.9	39
63	The longitudinal impact of depression on disability in Parkinson disease. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 458-465.	2.7	43
64	Evaluating and managing sleep disorders in the parkinson's disease clinic. <i>Basal Ganglia</i> , 2016, 6, 165-172.	0.3	5
65	Clinicopathological Correlates in a <i>PRNP</i> P102L Mutation Carrier with Rapidly Progressing Parkinsonism-Dystonia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 355-358.	1.5	6
66	Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 321.	9.0	77
67	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. <i>Telemedicine Journal and E-Health</i> , 2016, 22, 590-598.	2.8	47
68	A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. <i>Journal of Neurology</i> , 2016, 263, 772-780.	3.6	18
69	Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease.. <i>Neuropsychology</i> , 2015, 29, 622-631.	1.3	24
70	The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 351-359.	2.8	16
71	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1885-1892.	3.9	52
72	Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 371-378.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Validation of an Ambulatory Capacity Measure in Parkinson Disease: A Construct Derived from the Unified Parkinson's Disease Rating Scale. <i>Journal of Parkinson's Disease</i> , 2015, 5, 67-73.	2.8	16
74	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 584.	7.4	192
75	How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 1728-1732.	0.9	4
76	Altering Effort Costs in Parkinson's Disease with Noninvasive Cortical Stimulation. <i>Journal of Neuroscience</i> , 2015, 35, 12287-12302.	3.6	26
77	Tourette syndrome deep brain stimulation: A review and updated recommendations. <i>Movement Disorders</i> , 2015, 30, 448-471.	3.9	236
78	An Update and Review of the Treatment of Myoclonus. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 512.	4.2	21
79	Clinico-Pathological Correlation in Progressive Ataxia and Palatal Tremor: A Novel Tauopathy. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 50-56.	1.5	17
80	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	9.0	312
81	Mobility, mood and site of care impact health related quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 274-279.	2.2	9
82	Poster 350 A Random Effect Mixed Treatment Comparison (MTC) to Compare the Efficacy of Botulinum Toxin Type A Treatments for Cervical Dystonia. <i>PM and R</i> , 2014, 6, S307.	1.6	0
83	The past, present, and future of telemedicine for Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 871-883.	3.9	141
84	Application of pattern recognition framework for quantification of Parkinson's disease in DAT SPECT imaging. , 2014, , .		2
85	No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. <i>PLoS ONE</i> , 2014, 9, e112287.	2.5	12
86	REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 245.	2.0	6
87	Association of Cerebrospinal Fluid $\beta$ -Amyloid 1-42, T-tau, P-tau <sub>181</sub> , and $\alpha$ -Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 1277-87.	9.0	318
88	Long-term Botulinum toxin therapy for focal hand dystonia and reasons for discontinuation. <i>International Journal of Surgery</i> , 2013, 11, 657.	2.7	0
89	Diffusion, spread, and migration of botulinum toxin. <i>Movement Disorders</i> , 2013, 28, 1775-1783.	3.9	147
90	Myoclonus and Dystonia and Silver-Russell syndrome resulting from maternal uniparental disomy of chromosome 7. <i>Clinical Genetics</i> , 2013, 84, 368-372.	2.0	14

#	ARTICLE	IF	CITATIONS
91	Thalamic post-inhibitory bursting occurs in patients with organic dystonia more often than controls. Brain Research, 2013, 1541, 81-91.	2.2	5
92	Clinical Reasoning: A 57-year-old man with jaw spasms. Neurology, 2013, 80, e104-7.	1.1	0
93	The Preoperative Neurological Evaluation. Neurohospitalist, The, 2013, 3, 209-220.	0.8	11
94	Widespread abnormality of the $\hat{1}^3$ -aminobutyric acid-ergic system in Tourette syndrome. Brain, 2012, 135, 1926-1936.	7.6	166
95	Intact implicit probabilistic sequence learning in obstructive sleep apnea. Journal of Sleep Research, 2012, 21, 396-401.	3.2	25
96	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
97	Perception of Phosphenes and Flashed Alphabetical Characters is Enhanced by Single-Pulse Transcranial Magnetic Stimulation of Anterior Frontal Lobe: The Thalamic Gate Hypothesis. Perception, 2008, 37, 375-388.	1.2	9
98	Psychogenic palatal tremor. Movement Disorders, 2006, 21, 274-276.	3.9	39
99	Asymmetric spatiotemporal patterns of event-related desynchronization preceding voluntary sequential finger movements: a high-resolution EEG study. Clinical Neurophysiology, 2005, 116, 1213-1221.	1.5	142
100	Identifying true brain interaction from EEG data using the imaginary part of coherency. Clinical Neurophysiology, 2004, 115, 2292-2307.	1.5	1,529